Holen Sie sich die Stockscreener-App
108.26
0.70%
0.75
Handel nachbörslich:
106.68
-1.58
-1.46%
Schlusskurs vom Vortag:
$107.51
Offen:
$107.09
24-Stunden-Volumen:
998.48K
Relative Volume:
0.83
Marktkapitalisierung:
$25.35B
Einnahmen:
$2.97B
Nettoeinkommen (Verlust:
$-812.83M
KGV:
-31.88
EPS:
-3.3962
Netto-Cashflow:
$-1.24B
1W Leistung:
+3.30%
1M Leistung:
-4.28%
6M Leistung:
-6.11%
1J Leistung:
+37.46%
1-Tages-Spanne:
$106.07
$108.54
1-Wochen-Bereich:
$104.26
$109.68
52-Wochen-Spanne:
$76.53
$131.49
Biontech Se Adr Stock (BNTX) Company Profile
Vergleichen Sie BNTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
108.26 | 25.35B | 2.97B | -812.83M | -1.24B | -3.3962 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Bestätigt | H.C. Wainwright | Buy |
| 2025-05-29 | Eingeleitet | Goldman | Neutral |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-01-10 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-11-19 | Eingeleitet | Berenberg | Buy |
| 2024-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Hochstufung | Goldman | Neutral → Buy |
| 2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-14 | Eingeleitet | Evercore ISI | In-line |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-05 | Eingeleitet | Oppenheimer | Perform |
| 2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
| 2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-17 | Eingeleitet | Cowen | Market Perform |
| 2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
| 2021-05-18 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-08-03 | Fortgesetzt | Berenberg | Buy |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
| 2019-11-04 | Eingeleitet | Berenberg | Buy |
| 2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-11-04 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
BioNTech (BNTX) – Analysts’ Recent Ratings Changes - Defense World
Equities Analysts Issue Forecasts for BioNTech Q4 Earnings - Defense World
Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com
HC Wainwright Estimates BioNTech’s Q4 Earnings (NASDAQ:BNTX) - Defense World
Market Update: Abercrombie & Fitch Co (ANF) Sees Positive Movement, Closing at 75.00 - DWinneX
Gaining Ground: fuboTV Inc (FUBO) Closes Higher at 3.26, Up 2.84 - DWinneX
Market Resilience: Nerdy Inc (NRDY) Finishes Strong at 1.63, Up 2.52 - DWinneX
5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga
Riding the Waves: A Guide to Investing in ARBE Stock - investchronicle.com
BMY Reports Positive Data On Sotyktu From Arthritis Study - Barchart.com
Erasca Inc (ERAS) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Vaccine stocks muted as investors assess Kennedy’s overhaul of key panel - The Globe and Mail
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading - Benzinga
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio? - The Globe and Mail
Is BioNTech Stock A Buy On Major $11 Billion Cancer-Drug Deal? - Barchart.com
Bristol Myers Collaborates With BNTX for Oncology Candidate - sharewise
Bristol Myers Collaborates With BNTX For Oncology Candidate - Barchart.com
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results - Yahoo Finance
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
Bristol-Myers and BioNTech: Oncology Collaboration Further Solidifies BNT327's Potential - Morningstar
MRNA Seeks FDA Nod for Updated COVID-19 Vaccine - Yahoo Finance
BioNTech’s SWOT analysis: oncology pipeline and mRNA tech drive stock potential - Investing.com
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards For COVID-19 Shots - Barchart.com
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots - Zacks Investment Research
BioNTech to invest up to £1bn in UK R&D expansion - Sharecast.com
Market news - investments.halifax.co.uk
Bybit Gold & FX now supports stock trading: Explore new markets! - Bybit Announcement
BioNTech SE ADR (NASDAQ: BNTX): Getting A Free Pass? - Stocksregister
Balance Sheet Breakdown: BioNTech SE ADR (BNTX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Why BioNTech Stock Got Trounced On Tuesday - Barchart.com
BioNTech SE Reports Q1 2025 Financial Results - TipRanks
BioNTech’s Earnings Call: Oncology Progress Amid Financial Challenges - TipRanks
BioNTech Earnings: Guidance Reiterated, Oncology Development Continues to Advance - Morningstar
BioNTech SE ADR [NASDAQ: BNTX] Sees Increase in Stock Value - knoxdaily.com
HRL Shares Experience Surge in Value - knoxdaily.com
Nordson Corp [NDSN] stock for 268,620 USD was sold by Lovass Stephen - knoxdaily.com
Hanesbrands Inc [HBI] Records 200-Day SMA of $6.81 - knoxdaily.com
Ratio Review: Analyzing Regency Centers Corporation (REG)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Financial Metrics Exploration: Understanding MARA Holdings Inc (MARA) Through Ratios - DWinneX
Financial Fitness Check: Examining BioNTech SE ADR (BNTX)’s Key Ratios - DWinneX
The growth track for BioNTech SE ADR (BNTX) has changed recently - Sete News
Financial Health Report: Arthur J. Gallagher & Co (AJG)’s Ratios Tell a Tale - DWinneX
Financial Fitness Check: Examining B. Riley Financial Inc (RILY)’s Key Ratios - DWinneX
Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales - sharewise
A year in review: BioNTech SE ADR (BNTX)’s performance in the last year - uspostnews.com
BioNTech SE ADR (NASDAQ: BNTX) Could Make Significant Gains? - Marketing Sentinel
Investors Could Make -86.23% On NOV Inc (NYSE: NOV) Stock - Marketing Sentinel
Let’s Start With The Stock Forecast For UroGen Pharma Ltd (NASDAQ: URGN) - Marketing Sentinel
Is Murphy Oil Corp (NYSE: MUR) Stock Set To Rise More? - Marketing Sentinel
Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
BioNTech SE ADR (BNTX) Stock: A Year of Market Fluctuations - investchronicle.com
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):